英科医疗科技股份有限公司 证券代码：300677 证券简称：英科医疗 公告编号：2025-125 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 9 月 19 日召开第三届董事会第二十五次会议和第三届监事会第二十三 次会议，审议通过了《关于公司回购股份方案的议案》，同意公司使 用不低于人民币 8,000 万元（含本数）且不超过人民币 12,000 万元（含 本数）的自有资金，以集中竞价交易的方式回购部分公司股份（人民 币普通股（A 股）股票），用于实施员工持股计划及/或股权激励。 回购价格不超过人民币 26.51 元/股（含本数），回购股份的数量和金 额以回购期限届满时实际回购的股份数量和金额为准。回购股份的实 施期限为自公司第三届董事会第二十五次会议审议通过本次回购股 份方案之日起不超过 12 个月。具体内容详见公司分别于 2024 年 9 月 19 日、2024 年 9 月 20 日、2024 年 10 月 31 日、2025 年 6 月 13 日披 露于巨潮资讯网（www ...

（文章来源：证券日报） 证券日报网讯 9月2日晚间，英科医疗发布公告称，公司控股股东刘方毅先生将其所持有的部分股份办 理了质押手续。本次质押股数为7，360，000股，占其所持股份比例3.18%，占公司总股本比例1.12%。 质押方为国金证券股份有限公司，质押用途为个人资金需求。 ...

投资要点 ❑ 英科医疗披露 2025H1 业绩： 2025H1 公司实现营业收入 49.13 亿元，同比+9%，实现归母净利润 7.10 亿元，同 比+21%，扣非后归母净利润 4.00 亿元，同比-18%；25Q2 单季公司实现营业收入 24.20 亿元，同比+5%，实现归母净利润 3.58 亿元，同比+2.5%，扣非后归母净利 润 1.54 亿元，同比-53%。 证券研究报告 | 公司点评 | 医疗器械 英科医疗(300677) 报告日期：2025 年 09 月 02 日 经营韧性凸显，盈利弹性可期 ——英科医疗 2025H1 业绩点评报告 ❑ 扣非后下滑较多主要受理财公允价值变动计入非经影响 25Q2公司交易性金融资产增多，交易性金融资产109亿元，同比增长55.4亿元。 而交易性金融资产的公允价值变动收益更多计入非经常性损益。2025H1 公司金 融资产&金融负债产生的公允价值变动收益 2.28 亿元，同比+151%，因此对扣非 后归母净利润的影响较大。25Q2 单季我们测算公司主营业务净利润（剔除息差 收入/汇兑/理财等因素影响）2.3 亿元，表现符合我们预期。 ❑ Q2 为公司业绩低点，看好下半年 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-124 三、其他说明 本次变更事项系因基金根据整体投资规划、部分项目转让退出而 作出的调整，不存在损害公司及全体股东合法利益的情形，不会对公 司的财务状况及经营成果产生重大不利影响。 英科医疗科技股份有限公司 关于参与投资海宁擎川创业投资合伙企业（有限合伙） 的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、投资基金概述 为进一步优化投资结构，提升投资价值，英科医疗科技股份有限 公司（以下简称"英科医疗"或"公司"）与上海融玺创业投资管理 有限公司签署《海宁擎川创业投资合伙企业（有限合伙）合伙协议》， 以自有资金投资海宁擎川创业投资合伙企业（有限合伙）（以下简称 "合伙企业"或"基金"）。合伙企业的认缴出资总额为不超过 22,000 万元（币种为人民币，下同），其中，公司作为该合伙企业的有限合 伙人（LP）认缴出资 3,000 万元。具体内容详见公司于 2021 年 10 月 27 日刊登在巨潮资讯网（www.cninfo.com.cn）的《关于参与投资海 宁擎川创业投资合伙企业（有限合伙 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-123 英科医疗科技股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于近日接到公 司控股股东刘方毅先生的通知，获悉刘方毅先生将其所持有的公司部 分股份办理了质押手续。现将具体内容公告如下： 注：本公告总股本数以截至 2025 年 8 月 29 日公司最新总股本 654,793,743 股为计算标 准。 二、股东股份累计质押的情况 截至本公告披露日，刘方毅先生所持股份累计质押情况如下： | | | | 本次质押 | 本次质押 | 占其 | 占公 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 持股数量 | 持股 | 前质押股 | 后质押股 | 所持 | 司总 | 已质押股 | 占已 | 未质押股份 | 占未质 | | 称 | （股） | 比例 | 份数量 | 份数 ...

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

Core Viewpoint - In the recent financial report, Yingke Medical (300677) demonstrated solid growth in revenue and net profit, indicating improved profitability and operational efficiency [1]. Financial Performance - As of the end of the reporting period, the company's total revenue reached 4.913 billion yuan, an increase of 8.9% year-on-year [1]. - The net profit attributable to shareholders was 714 million yuan, reflecting a year-on-year growth of 21.02% [1]. - In Q2 alone, total revenue was 2.42 billion yuan, up 4.79% year-on-year, while net profit for the quarter was 358 million yuan, a 2.55% increase [1]. - The gross margin improved to 24.23%, with a year-on-year increase of 10.65%, and the net margin rose to 14.79%, up 12.72% year-on-year [1]. Cost and Efficiency Metrics - Total selling, administrative, and financial expenses amounted to 429 million yuan, accounting for 8.74% of revenue, which is a significant increase of 108.64% year-on-year [1]. - Earnings per share (EPS) increased to 1.12 yuan, a rise of 24.44% year-on-year, while operating cash flow per share surged to 1.13 yuan, reflecting a remarkable increase of 165.56% [1]. Asset and Liability Overview - The company reported cash and cash equivalents of 11.738 billion yuan, a 4.36% increase from the previous year [1]. - Accounts receivable stood at 1.363 billion yuan, up 2.75% year-on-year [1]. - Interest-bearing liabilities rose significantly to 17.671 billion yuan, marking a 61.74% increase [1]. Investment Insights - The company's return on invested capital (ROIC) was reported at 4.65%, indicating a relatively weak capital return, although the net profit margin was strong at 15.66% [3]. - Historical data shows that the median ROIC since the company went public is 11.49%, suggesting potential for better investment returns in the future [3]. - Analysts project that the company's performance for 2025 will yield a net profit of 1.413 billion yuan, with an average EPS forecast of 2.17 yuan [3]. Fund Holdings - The largest fund holding Yingke Medical is the GF聚瑞混合A, with 3.3198 million shares held, remaining unchanged [4]. - Other funds have shown varied movements, with some increasing their holdings while others have reduced their positions [4].

Core Insights - In the recent interim report for 2025, the company reported a total revenue of 4.913 billion yuan, an increase of 8.9% year-on-year, and a net profit attributable to shareholders of 710 million yuan, up 21.02% year-on-year [1] - The second quarter showed a total revenue of 2.42 billion yuan, a year-on-year increase of 4.79%, and a net profit of 358 million yuan, up 2.55% year-on-year [1] - The company's profitability improved, with a gross margin of 24.23%, an increase of 10.65% year-on-year, and a net margin of 14.79%, up 12.72% year-on-year [1] Financial Performance - Total operating expenses, including sales, management, and financial expenses, amounted to 429 million yuan, representing 8.74% of revenue, which is an increase of 108.64% year-on-year [1] - Earnings per share (EPS) reached 1.12 yuan, a year-on-year increase of 24.44% [1] - The company's net asset per share was 27.33 yuan, up 6.86% year-on-year, and operating cash flow per share was 1.13 yuan, an increase of 165.56% year-on-year [1] Business Evaluation - The company's return on invested capital (ROIC) was 4.65%, indicating a relatively weak capital return, while the net profit margin was 15.66%, suggesting high added value in products or services [3] - Historical data shows a median ROIC of 11.49% since the company went public, with the lowest ROIC recorded in 2023 at 1.01% [3] - The company has a healthy cash asset position, but its performance heavily relies on capital expenditures, necessitating careful monitoring of capital spending projects [3] Debt and Cash Flow Analysis - The average operating cash flow over the past three years is only 4.91% of current liabilities, indicating potential cash flow concerns [3] - The interest-bearing asset-liability ratio has reached 44.74%, and the ratio of interest-bearing debt to the average operating cash flow over the past three years is 20.04% [3] - Accounts receivable have reached 93.01% of profit, highlighting a potential risk in receivables management [3] Fund Holdings - The largest fund holding in the company is the GF聚瑞混合A, with 3.3198 million shares held, remaining unchanged [4] - Other funds have shown varied movements, with some reducing their holdings while others have increased their positions [4] - The fund's recent performance indicates a 70.23% increase over the past year, with a current scale of 1.464 billion yuan [4]

（编辑 姚尧） 证券日报网讯 8月29日晚间，英科医疗发布公告称，公司及子公司不存在对合并报表范围外单位提供担 保的事项，不存在逾期担保的情况，亦不涉及诉讼的担保金额及因担保被判决败诉而应承担的担保金额 等。 ...

从股价来看，2025年3月31日至2025年6月30日，英科医疗区间跌幅为0.45%，在此期间股东户数减少 1828.0户，减幅为2.96%。 证券之星消息，近日英科医疗披露，截至2025年6月30日公司股东户数为6.0万户，较3月31日减少1828.0 户，减幅为2.96%。户均持股数量由上期的1.05万股增加至1.08万股，户均持股市值为25.52万元。 在医疗器械行业个股中，英科医疗股东户数高于行业平均水平，截至6月30日，医疗器械行业平均股东 户数为2.19万户。户均持股市值方面，医疗器械行业A股上市公司户均持股市值为46.93万元，英科医疗 低于行业平均水平。 根据统计，英科医疗2025年3月31日至2025年6月30日，主力资金净流出2.68亿元，游资资金净流入 1711.07万元，散户资金净流入2.51亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | | | | 统计截止日｜区间股价涨跌幅｜股东户数｜增减｜增减比例｜户均持股市值（元）｜户均持股数（股) | | | | | --- | --- | --- | ...